Trial
NCT03522584
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of Washington
Collaborators
National Cancer Institute (NCI); AstraZeneca
Condition
Metastatic Head and Neck Squamous Cell Carcinoma
Intervention
Durvalumab
Why stopped
Terminated by the sponsor due to lack of efficacy in study treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-12